Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 1/2007

01.01.2007 | Original Paper

Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and γ-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells

verfasst von: Shin-ichiro Masunaga, Hideko Nagasawa, Kenji Nagata, Minoru Suzuki, Yoshihiro Uto, Hitoshi Hori, Yuko Kinashi, Koji Ono

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The effect of vascular disrupting agent ZD6126 with time on the sensitivity to the hypoxic cytotoxin tirapazamine (TPZ) and γ-rays was examined in large and small solid tumors.

Methods

Mice bearing SCC VII tumors 1 or 1.5 cm in diameter received 5-bromo-2′-deoxyuridine (BrdU) continuously to label all proliferating (P) cells, followed by injection with or without ZD6126. In the absence of ZD6126, or 1 or 24 h following ZD6126 injection, the response to TPZ or γ-ray irradiation in quiescent (Q) cells was assessed in terms of induced micronucleus (MN) frequency using immunofluorescence staining for BrdU. The MN frequency in the total cell population was determined from the tumors not pretreated with BrdU. Another group of tumor-bearing mice received a series of test doses of γ-rays while alive or after tumor clamping to obtain hypoxic fractions (HFs) in the tumors.

Results

One hour after ZD6126 injection, both small and large tumors showed lower and higher sensitivity, and 24 h after, higher and lower sensitivity, to γ-rays and TPZ, respectively, than the tumors not treated with ZD6126. Further, they showed larger and smaller HFs 1 and 24 h after ZD6126 injection, respectively. Without ZD6126 and 1 h after injection, small tumors were more sensitive to γ-rays and less sensitive to TPZ than large tumors, probably due to the smaller HFs than large tumors. In contrast, 24 h after the injection, these differences in sensitivity and the HF between small and large tumors were reversed. The changes in sensitivity and the size of the HF were more marked in the total cell population than in Q cells.

Conclusions

Following ZD6126 treatment, in terms of tumor control, especially large tumors and total tumor cell population, administering TPZ 1 h later and γ-ray irradiation 24 h later were effective. Intratumor physiologic factors such as the size of the HF, depending on the time after ZD6126 injection, have to be taken into account when combining another treatment with ZD6126.
Literatur
Zurück zum Zitat Ando K, Koike S, Ohira C, Chen YJ, Nojima K, Ando S, Ohbuchi T, Kobayashi N, Shimizu W, Urano M (1999) Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Int J Radiat Biol 75:505–512PubMedCrossRef Ando K, Koike S, Ohira C, Chen YJ, Nojima K, Ando S, Ohbuchi T, Kobayashi N, Shimizu W, Urano M (1999) Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Int J Radiat Biol 75:505–512PubMedCrossRef
Zurück zum Zitat Blakey DC, Westwood FR, Walker, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974–1983PubMed Blakey DC, Westwood FR, Walker, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974–1983PubMed
Zurück zum Zitat Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA (2002) ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247–7253PubMed Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA (2002) ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247–7253PubMed
Zurück zum Zitat Denekamp J (1993) Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181–196PubMedCrossRef Denekamp J (1993) Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181–196PubMedCrossRef
Zurück zum Zitat Grosios K, Holwell SE, McGown AT, Petti GR, Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318–1327PubMedCrossRef Grosios K, Holwell SE, McGown AT, Petti GR, Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318–1327PubMedCrossRef
Zurück zum Zitat Horsman MR, Murata R (2003) Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57:1047–1055PubMedCrossRef Horsman MR, Murata R (2003) Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57:1047–1055PubMedCrossRef
Zurück zum Zitat Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M, Giaccia A (2001) Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21:1297–1310PubMedCrossRef Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M, Giaccia A (2001) Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21:1297–1310PubMedCrossRef
Zurück zum Zitat Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR (1988) Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethyl-xanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78:439–445 Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR (1988) Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethyl-xanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78:439–445
Zurück zum Zitat Masunaga S, Ono K (2002) Significance of the response of quiescent cell populations within solid tumors in cancer therapy. J Radiat Res 43:11–25PubMedCrossRef Masunaga S, Ono K (2002) Significance of the response of quiescent cell populations within solid tumors in cancer therapy. J Radiat Res 43:11–25PubMedCrossRef
Zurück zum Zitat Masunaga S, Ono K Hori H, Kinashi Y, Suzuki M, Takagaki M, Kasai S Nagasawa H, Uto Y (1999) Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells. Int J Hyperthermia 15:7–16PubMedCrossRef Masunaga S, Ono K Hori H, Kinashi Y, Suzuki M, Takagaki M, Kasai S Nagasawa H, Uto Y (1999) Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells. Int J Hyperthermia 15:7–16PubMedCrossRef
Zurück zum Zitat Micheletti G, Poli M, Borsotti DC, Martinelli M, Imberti B, Taraboletti G, Giavazzi R (2003) Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63:1534–1537PubMed Micheletti G, Poli M, Borsotti DC, Martinelli M, Imberti B, Taraboletti G, Giavazzi R (2003) Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63:1534–1537PubMed
Zurück zum Zitat Moulder JE, Rockwell S (1984) Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10:695–712PubMed Moulder JE, Rockwell S (1984) Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10:695–712PubMed
Zurück zum Zitat Seng F, Ley K (1972) Simple synthesis of 3-amino-1,2,4-benzotriazine-1,4-dioxide. Angew Chem Int Ed Engl 11:1009–1010 Seng F, Ley K (1972) Simple synthesis of 3-amino-1,2,4-benzotriazine-1,4-dioxide. Angew Chem Int Ed Engl 11:1009–1010
Zurück zum Zitat Shibamoto Y, Yukawa Y, Tsutsui K, Takahashi M, Abe M (1986) Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res 77:908–15PubMed Shibamoto Y, Yukawa Y, Tsutsui K, Takahashi M, Abe M (1986) Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res 77:908–15PubMed
Zurück zum Zitat Siemann DW, Rojiani AM (2005) The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 62:846–853PubMedCrossRef Siemann DW, Rojiani AM (2005) The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 62:846–853PubMedCrossRef
Zurück zum Zitat Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100:2491–2499PubMedCrossRef Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100:2491–2499PubMedCrossRef
Zurück zum Zitat Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FALM, Horsman MR, Marme D, LoRusso PM (2005) Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11:416–420PubMed Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FALM, Horsman MR, Marme D, LoRusso PM (2005) Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11:416–420PubMed
Zurück zum Zitat Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP. (2006) Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res 66:2074–2080PubMedCrossRef Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP. (2006) Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res 66:2074–2080PubMedCrossRef
Zurück zum Zitat Vaupel P (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14:198–206PubMedCrossRef Vaupel P (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14:198–206PubMedCrossRef
Zurück zum Zitat Wilson WR, Li AE, Cowan DS, Siim BG (1998) Enhancement of tumor radiation response by the antivascular agent 5,6-dimethyl-xanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42:905–908PubMedCrossRef Wilson WR, Li AE, Cowan DS, Siim BG (1998) Enhancement of tumor radiation response by the antivascular agent 5,6-dimethyl-xanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42:905–908PubMedCrossRef
Zurück zum Zitat Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239–1242PubMed Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239–1242PubMed
Zurück zum Zitat Zhao D, Jiang L, Hahn EW, Mason RP (2005a) Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 62:872–880CrossRef Zhao D, Jiang L, Hahn EW, Mason RP (2005a) Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 62:872–880CrossRef
Zurück zum Zitat Zhao L, Ching L-M, Kestell P, Kelland LR, Baguley BC (2005b) Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenine-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer 116:322–326CrossRef Zhao L, Ching L-M, Kestell P, Kelland LR, Baguley BC (2005b) Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenine-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer 116:322–326CrossRef
Metadaten
Titel
Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and γ-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells
verfasst von
Shin-ichiro Masunaga
Hideko Nagasawa
Kenji Nagata
Minoru Suzuki
Yoshihiro Uto
Hitoshi Hori
Yuko Kinashi
Koji Ono
Publikationsdatum
01.01.2007
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2007
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-006-0145-1

Weitere Artikel der Ausgabe 1/2007

Journal of Cancer Research and Clinical Oncology 1/2007 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.